Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Price, News & Analysis

ARCA biopharma logo

About ARCA biopharma Stock (NASDAQ:ABIO)

Key Stats

Today's Range
N/A
50-Day Range
$2.40
$599.04
52-Week Range
N/A
Volume
290,800 shs
Average Volume
607,995 shs
Market Capitalization
$34.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

I've got news for you…
Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week
FMR LLC Acquires New Stake in ARCA biopharma Inc
See More Headlines

ABIO Stock Analysis - Frequently Asked Questions

ARCA biopharma, Inc. (NASDAQ:ABIO) posted its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) EPS for the quarter, topping analysts' consensus estimates of ($341.28) by $292.32.

Shares of ARCA biopharma reverse split before market open on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Block (SQ), Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), Palantir Technologies (PLTR), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/04/2021
Dividend Payable
8/28/2024
Ex-Dividend for 8/28 Dividend
8/29/2024
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABIO
Employees
6
Year Founded
N/A

Profitability

Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.25 per share

Miscellaneous

Free Float
10,024,000
Market Cap
$34.82 million
Optionable
Optionable
Beta
0.91
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ABIO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners